LeMaitre Vascular, Inc. filed its quarterly report on Form 10-Q with the SEC on August 5, 2026, covering the three- and six-month periods ended June 30, 2026, for its common stock listed on The Nasdaq Global Market under the ticker LMAT.

Key Highlights

  • Q2 net sales: The company reported net sales of $70,382 thousand for the three months ended June 30, 2026, compared with $64,232 thousand for the same period in 2025.
  • Q2 net income: Net income for the second quarter of 2026 was $17,050 thousand, up from $13,779 thousand in Q2 2025.
  • Six-month net income: For the six months ended June 30, 2026, net income totaled $32,729 thousand, versus $24,790 thousand for the comparable 2025 period.
  • Diluted EPS: Diluted earnings per share were $0.74 for Q2 2026 and $1.42 for the six-month period ended June 30, 2026, according to the filing.
  • Dividend declared: Cash dividends declared per common share were $0.25 for Q2 2026 and $0.50 for the six-month period ended June 30, 2026.
  • Shares outstanding: As of the balance sheet date, 22,864,935 shares of common stock were outstanding, with 24,494,202 shares issued and 1,629,267 shares held as treasury stock.

LeMaitre Vascular Q2 2026 Income Statement and Balance Sheet Overview

According to the filing, LeMaitre Vascular generated net sales of $70,382 thousand in the three months ended June 30, 2026, compared with $64,232 thousand in the prior-year quarter. Gross profit for Q2 2026 was $50,764 thousand, against $44,974 thousand in Q2 2025. Income from operations for the quarter was $20,399 thousand, up from $16,142 thousand a year earlier. The company also reported investment income of $3,386 thousand and interest expense of $2,602 thousand for the six-month period, per the filing.

The consolidated balance sheet as of June 30, 2026, showed total assets of $640,549 thousand and total liabilities of $220,207 thousand, according to the filing. Total stockholders' equity was $420,342 thousand at June 30, 2026, compared with $393,516 thousand at December 31, 2025. Retained earnings grew to $206,017 thousand from $184,715 thousand at year-end 2025. Goodwill was reported at $65,945 thousand at both dates. The filing also discloses that cash and cash equivalents were $26,625 thousand at June 30, 2026, compared with $28,244 thousand at December 31, 2025.

Operating expenses for the second quarter of 2026 totaled $30,365 thousand, including sales and marketing of $14,408 thousand, general and administrative expenses of $11,110 thousand, and research and development of $4,847 thousand, per the filing. The provision for income taxes for Q2 2026 was $5,139 thousand, resulting in net income of $17,050 thousand. For the six-month period, the company reported a provision for income taxes of $9,132 thousand and net income of $32,729 thousand.

What Was Disclosed

LeMaitre Vascular's 10-Q for the quarter ended June 30, 2026, disclosed financial statements including income from operations, balance sheet figures, stockholders' equity activity, earnings per share, and dividend declarations for both the three- and six-month periods ended June 30, 2026.